Handelsbanken Fonder AB Has $24.66 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Handelsbanken Fonder AB lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 38.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,586 shares of the medical research company’s stock after selling 66,654 shares during the quarter. Handelsbanken Fonder AB’s holdings in IQVIA were worth $24,662,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in IQV. AdvisorNet Financial Inc increased its holdings in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new stake in IQVIA in the 4th quarter valued at $32,000. Activest Wealth Management bought a new stake in IQVIA in the 4th quarter valued at $35,000. CVA Family Office LLC bought a new stake in IQVIA in the 4th quarter valued at $43,000. Finally, CoreFirst Bank & Trust bought a new stake in shares of IQVIA during the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Evercore ISI upped their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Truist Financial boosted their price target on IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Robert W. Baird upped their target price on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Finally, BTIG Research started coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Trading Up 1.4 %

NYSE IQV opened at $231.34 on Tuesday. The business has a 50 day simple moving average of $245.08 and a 200 day simple moving average of $222.28. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The stock has a market capitalization of $41.99 billion, a P/E ratio of 31.73, a P/E/G ratio of 2.21 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter last year, the firm posted $2.54 earnings per share. The firm’s revenue was up 3.5% on a year-over-year basis. Research analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.